| Literature DB >> 27396647 |
Irina Ghislain1, Efstathios Zikos2, Corneel Coens3, Chantal Quinten2, Vasiliki Balta4, Konstantinos Tryfonidis3, Martine Piccart5, Dimitrios Zardavas6, Eva Nagele7, Vesna Bjelic-Radisic7, Fatima Cardoso8, Mirjam A G Sprangers9, Galina Velikova10, Andrew Bottomley3.
Abstract
Breast cancer is the leading cause of cancer death among women worldwide, and increasingly, randomised controlled trials of this disease are measuring the health-related quality of life of these patients. In this systematic Review, we assess the adequacy of methods used to report health-related quality of life (HRQOL) from 49 eligible randomised controlled trials of advanced breast cancer. We compare our findings with those from the literature to investigate whether the standard of HRQOL reporting in this field has changed. We conclude that the overall reporting of HRQOL has improved, but some crucial aspects remain problematic, such as the absence of HRQOL research hypotheses and the overemphasis on statistical rather than clinical significance. Additionally, new challenges are arising with the emergence of novel treatments and the advent of personalised medicine, and improved HRQOL tools are required to cover the range of side-effects of newer therapies.Entities:
Mesh：
Year: 2016 PMID： 27396647 DOI： 10.1016/S1470-2045(16)30099-7
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316